KDM1A and acute myeloid leukemia: Among many combinatorial approaches being tested in preclinical settings, a combination of Ruxolitinib with Lysine Specific Demethylase 1 (LSD1) inhibitor recently demonstrated a synergistic survival improvement in mouse models of CEBPA- and CSF3R-mutated AML [97].